Abiopharma

Firefly Neuroscience, Inc. is an artificial intelligence (AI) technology company dedicated to developing neuroscientific solutions that enhance outcomes for patients with mental illnesses and neurological disorders. The Company has developed its FDA-510(k) cleared Brain Network Analytics (BNA) software platform (the BNA Platform) and is focused on advancing diagnostic and treatment approaches for people suffering from mental illnesses and cognitive disorders, including depression, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder (ADHD). BNA, utilizing AI and an extensive proprietary electroencephalogram (EEG) database, combines the automatic analysis of Event Related Potentials (ERPs), spectral EEG and behavioral performance data for a comprehensive, and objective data-driven brain health evaluation. The BNA Platform, in conjunction with an FDA-cleared EEG system, can provide clinicians with comprehensive insights into brain function (cognition).

Additional info from NASDAQ:
Firefly Neuroscience, Inc. is an artificial intelligence (AI) technology company dedicated to developing neuroscientific solutions that enhance outcomes for patients with mental illnesses and neurological disorders. The Company has developed its FDA-510(k) cleared Brain Network Analytics (BNA) software platform (the BNA Platform) and is focused on advancing diagnostic and treatment approaches for people suffering from mental illnesses and cognitive disorders, including depression, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder (ADHD). BNA, utilizing AI and an extensive proprietary electroencephalogram (EEG) database, combines the automatic analysis of Event Related Potentials (ERPs), spectral EEG and behavioral performance data for a comprehensive, and objective data-driven brain health evaluation. The BNA Platform, in conjunction with an FDA-cleared EEG system, can provide clinicians with comprehensive insights into brain function (cognition).